This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

SparkCures ID	1338
Trial Phase	Phase 1
Enrollment	2 Patients
Treatments	VP301
Tags	Bispecific Antibody CD38 ICAM-1
Trial Sponsors	Virtuoso BINco, Inc.
NCT Identifier	NCT05698888

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

The following criteria is provided for health care professionals.

Inclusion Criteria:

Histologic diagnosis of a refractory solid tumor, refractory myeloma or lymphoma with measurable or evaluable disease
Patients must have progressed following all therapies of known, potential clinical benefit, or for whom treatments of known clinical benefit are contraindicated.
Adequate kidney, liver, and hematologic function
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2

Exclusion Criteria:

Active brain metastases and history of leptomeningeal metastases.
Myeloma patients with plasmacytoma as only measurable disease
Non-secretory myeloma
Patients with advanced metastatic, symptomatic, visceral spread who are at risk of life-threatening complications
Active or chronic, uncontrolled bacterial, viral, or fungal infection(s)
Abnormal ECG
Has clinically significant cardiovascular disease
Additional active malignancy that may confound the assessment of the study endpoints
Pregnancy or lactation
Known seropositivity for HIV (human immunodeficiency virus) or active hepatitis B or hepatitis C

Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors

Overview

Am I Eligible?

US Trial Locations